JP2007512847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007512847A5 JP2007512847A5 JP2006542834A JP2006542834A JP2007512847A5 JP 2007512847 A5 JP2007512847 A5 JP 2007512847A5 JP 2006542834 A JP2006542834 A JP 2006542834A JP 2006542834 A JP2006542834 A JP 2006542834A JP 2007512847 A5 JP2007512847 A5 JP 2007512847A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dsodn
- molecule
- seq
- flank1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 claims 18
- 125000003729 nucleotide group Chemical group 0.000 claims 18
- 238000000034 method Methods 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000002502 liposome Substances 0.000 claims 6
- 108091023040 Transcription factor Proteins 0.000 claims 4
- 102000040945 Transcription factor Human genes 0.000 claims 4
- 108091081021 Sense strand Proteins 0.000 claims 3
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 3
- 230000001772 anti-angiogenic effect Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 108090000565 Capsid Proteins Proteins 0.000 claims 2
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 claims 1
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- -1 AstraZeneca) Chemical compound 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 229940123038 Integrin antagonist Drugs 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 229940120638 avastin Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 230000010502 episomal replication Effects 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940084651 iressa Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000006444 vascular growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52686903P | 2003-12-03 | 2003-12-03 | |
| US61240604P | 2004-09-22 | 2004-09-22 | |
| PCT/US2004/040704 WO2005056795A2 (en) | 2003-12-03 | 2004-12-02 | Hif oligonucleotide decoy molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007305107A Division JP2008109935A (ja) | 2003-12-03 | 2007-11-26 | Ｈｉｆオリコヌクレオチドデコイ分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007512847A JP2007512847A (ja) | 2007-05-24 |
| JP2007512847A5 true JP2007512847A5 (https=) | 2008-01-24 |
Family
ID=34681516
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006542834A Pending JP2007512847A (ja) | 2003-12-03 | 2004-12-02 | Ｈｉｆオリコヌクレオチドデコイ分子 |
| JP2007305107A Pending JP2008109935A (ja) | 2003-12-03 | 2007-11-26 | Ｈｉｆオリコヌクレオチドデコイ分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007305107A Pending JP2008109935A (ja) | 2003-12-03 | 2007-11-26 | Ｈｉｆオリコヌクレオチドデコイ分子 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20050215503A1 (https=) |
| EP (1) | EP1709175A2 (https=) |
| JP (2) | JP2007512847A (https=) |
| WO (1) | WO2005056795A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7482158B2 (en) | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
| GEP20125516B (en) * | 2004-08-16 | 2012-05-25 | Quark Biotech Inc | Therapeutic uses of inhibitors of rtp801 |
| AU2005286640A1 (en) * | 2004-09-21 | 2006-03-30 | Anesiva, Inc. | Delivery of polynucleotides |
| CA2585268A1 (en) * | 2004-10-25 | 2006-05-04 | Ajay Verman | Methods for lowering hif-1 mediated gene expression |
| US20080306002A1 (en) * | 2005-08-18 | 2008-12-11 | The General Hospital Corporation | Combination Therapy for Preventing Angiogenesis |
| WO2008070616A2 (en) * | 2006-12-01 | 2008-06-12 | University Of Utah Research Foundation | METHODS AND COMPOSITIONS RELATED TO HIF-1α |
| AU2007341256B2 (en) | 2006-12-28 | 2012-09-20 | Allnex Netherlands B.V. | Waterborne polymeric dispersions |
| GB0719367D0 (en) * | 2007-10-03 | 2007-11-14 | Procarta Biosystems Ltd | Transcription factor decoys, compositions and methods |
| TW201010732A (en) * | 2008-08-29 | 2010-03-16 | Enzon Pharmaceuticals Inc | Method of treating RAS associated cancer |
| KR20110075029A (ko) * | 2008-10-21 | 2011-07-05 | 엔즌 파마슈티칼스, 인코포레이티드 | 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료 |
| CN102395370A (zh) * | 2009-04-17 | 2012-03-28 | 安龙制药公司 | 用7-乙基-10-羟基喜树碱的多臂聚合缀合物抑制血管生成的方法 |
| WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
| WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
| KR102433981B1 (ko) * | 2020-12-15 | 2022-08-19 | 대구가톨릭대학교산학협력단 | HIF-1α 및 STAT5 전사인자를 억제하는 합성 디코이 올리고핵산 및 이를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6113946A (en) * | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
| US5922687A (en) * | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| US5882914A (en) * | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
| US6423493B1 (en) * | 1998-10-26 | 2002-07-23 | Board Of Regents The University Of Texas System | Combinatorial selection of oligonucleotide aptamers |
| US6395550B1 (en) * | 2000-01-10 | 2002-05-28 | Corgentech, Inc. | Method and apparatus for tissue treatment |
| DE10049549A1 (de) * | 2000-10-06 | 2002-05-02 | Markus Hecker | Modulation der Transkription pro-inflammatorischer Genprodukte |
| NZ520321A (en) * | 2002-07-19 | 2005-03-24 | Auckland Uniservices Ltd | Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal |
| AU2005286640A1 (en) * | 2004-09-21 | 2006-03-30 | Anesiva, Inc. | Delivery of polynucleotides |
-
2004
- 2004-12-02 EP EP04813083A patent/EP1709175A2/en not_active Withdrawn
- 2004-12-02 WO PCT/US2004/040704 patent/WO2005056795A2/en not_active Ceased
- 2004-12-02 JP JP2006542834A patent/JP2007512847A/ja active Pending
- 2004-12-02 US US11/003,907 patent/US20050215503A1/en not_active Abandoned
-
2007
- 2007-11-26 JP JP2007305107A patent/JP2008109935A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines | |
| Yin et al. | Targeting RNA: a transformative therapeutic strategy | |
| DK3305302T3 (en) | COMPOSITIONS AND PROCEDURES FOR MODULATING SMN2 SPLITING BY AN INDIVIDUAL | |
| EP2673286B1 (en) | Therapeutic compounds | |
| JP2007512847A5 (https=) | ||
| JP2009537129A (ja) | エキソンスキッピングを誘発する為の手段及び方法 | |
| CA3162618A1 (en) | Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases | |
| EP3128008A2 (en) | Novel double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases | |
| Philippen et al. | Antisense MicroRNA therapeutics in cardiovascular disease: quo vadis? | |
| AU2014284836A1 (en) | Respiratory disease-related gene specific siRNA, double-helical oligo RNA structure containing siRNA, compositon containing same for preventing or treating respiratory disease | |
| CN111918968A (zh) | Micro-RNA 22的抑制剂 | |
| JP7184649B2 (ja) | アプタマーによるポリアデニル化の調節を通じての遺伝子発現制御 | |
| Ou et al. | Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease | |
| JP2024511525A (ja) | Ｒｎａプラスミド送達システム及びその使用 | |
| JP2011510647A (ja) | 遺伝子発現の転写後抑制を相乗的に生じさせることができる方法および組成物 | |
| Selvaskandan et al. | Clinical application of microRNAs in glomerular diseases | |
| Teng et al. | Assembling the RNA therapeutics toolbox | |
| Cronin et al. | Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions | |
| Prins et al. | RNA-based therapeutic opportunities for the treatment of kidney diseases | |
| JP2025166191A (ja) | ハンチントン病を処置するための方法 | |
| JP2024534574A (ja) | ハプロ不全状態のための治療薬 | |
| US20230287427A1 (en) | Inhibition of lncExACT1 to Treat Heart Disease | |
| JP2022541212A (ja) | 治療的使用のための、ヒト遺伝子ＪＡＫ１又はＪＡＫ３の発現を標的とするＳｉＲＮＡ配列 | |
| JP7843053B2 (ja) | 核酸送達システム及びその使用 | |
| JP2025503910A (ja) | 神経疾患を処置するための組成物 |